Clinical Trial Update: A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of dasatinib in patients with advanced/metastatic breast cancer (triple-negative) completed; results were posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DASATINIB (Dasatinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Breast Cancer, Metastasis | Phase 2 | Status: COMPLETED | Results posted: 2011-03-15